U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C17H19N2O5S.K
Molecular Weight 402.506
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENETHICILLIN POTASSIUM

SMILES

[K+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C)OC3=CC=CC=C3)C([O-])=O

InChI

InChIKey=ORMNNUPLFAPCFD-DVLYDCSHSA-M
InChI=1S/C17H20N2O5S.K/c1-9(24-10-7-5-4-6-8-10)13(20)18-11-14(21)19-12(16(22)23)17(2,3)25-15(11)19;/h4-9,11-12,15H,1-3H3,(H,18,20)(H,22,23);/q;+1/p-1/t9?,11-,12+,15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C17H19N2O5S
Molecular Weight 363.408
Charge -1
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 3 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: doi: 10.1136/bmj.2.5197.534

Pheneticillin (phenoxyethylpenicillin) is an oral penicillin used for the treatment of upper respiratory tract infections; lower respiratory tract infections; skin and soft tissue infections. Pheneticillin inhibits the synthesis of the cell wall by inhibiting the penicillin binding proteins (PBPs) function. It is well absorbed from the gastrointestinal tract. It reaches the pleural and peritoneal cavities but doesn’t cross the blood-brain barrier. Diarrhea has sometimes occurred with therapeutic doses in man.

CNS Activity

Sources: doi: 10.1136/bmj.2.5197.534

Originator

Sources: DOI: 10.1136/bmj.2.5197.534

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Broxil

Approved Use

It is indicated for the treatment of infections, caused by susceptible microorganisms. In particular streptococcal infections, such as: upper respiratory tract infections (for example, pharyngitis); lower respiratory tract infections (for example, pneumonia); skin and soft tissue infections (for example, abscesses or impetigo).

Launch Date

1965
Curative
Broxil

Approved Use

It is indicated for the treatment of infections, caused by susceptible microorganisms. In particular streptococcal infections, such as: upper respiratory tract infections (for example, pharyngitis); lower respiratory tract infections (for example, pneumonia); skin and soft tissue infections (for example, abscesses or impetigo).

Launch Date

1965
Curative
Broxil

Approved Use

It is indicated for the treatment of infections, caused by susceptible microorganisms. In particular streptococcal infections, such as: upper respiratory tract infections (for example, pharyngitis); lower respiratory tract infections (for example, pneumonia); skin and soft tissue infections (for example, abscesses or impetigo).

Launch Date

1965
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23 μg/mL
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PHENETICILLIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29.3 μg × h/mL
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PHENETICILLIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
63 min
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PHENETICILLIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PHENETICILLIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg 4 times / day multiple, oral
Highest studied dose
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy, 54 (19–71)
n = 120
Health Status: unhealthy
Condition: Infection
Age Group: 54 (19–71)
Sex: M+F
Population Size: 120
Sources:
1 g 1 times / day single, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: single
Dose: 1 g, 1 times / day
Sources:
unhealthy, 58.3±15.4(19–90)
n = 84
Health Status: unhealthy
Condition: Infection
Age Group: 58.3±15.4(19–90)
Sex: M+F
Population Size: 84
Sources:
250 mg 3 times / day multiple, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: Infection
Age Group: adult
Sex: M+F
Population Size: 437
Sources:
Disc. AE: Dermatitis, Throbbing headache...
AEs leading to
discontinuation/dose reduction:
Dermatitis
Throbbing headache
Hypersensitivity reaction
Sources:
AEs

AEs

AESignificanceDosePopulation
Dermatitis Disc. AE
250 mg 3 times / day multiple, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: Infection
Age Group: adult
Sex: M+F
Population Size: 437
Sources:
Hypersensitivity reaction Disc. AE
250 mg 3 times / day multiple, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: Infection
Age Group: adult
Sex: M+F
Population Size: 437
Sources:
Throbbing headache Disc. AE
250 mg 3 times / day multiple, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: Infection
Age Group: adult
Sex: M+F
Population Size: 437
Sources:
PubMed

PubMed

TitleDatePubMed
[Simultaneous determination of five penicillins in muscle, liver and kidney from slaughtered animals using liquid chromatography coupled with electrospray ionization tandem mass spectrometry].
2003 Feb
Deacetoxycephalosporin C synthase isozymes exhibit diverse catalytic activity and substrate specificity.
2003 Jan 28
Patents

Patents

Sample Use Guides

250 mg every 8 hours
Route of Administration: Oral
In Vitro Use Guide
The MIC against S. aureus of Pheneticillin in broth was 0.031 mg/l.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:19:16 GMT 2023
Edited
by admin
on Fri Dec 15 15:19:16 GMT 2023
Record UNII
70978WUK7C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENETHICILLIN POTASSIUM
HSDB   MI  
Common Name English
Pheneticillin potassium [WHO-DD]
Common Name English
PHENETHICILLIN POTASSIUM [MI]
Common Name English
PHENETICILLIN POTASSIUM
MART.   WHO-DD  
Common Name English
Monopotassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxypropionamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
Systematic Name English
ASTRACILLIN
Common Name English
DRAMCILLIN S
Common Name English
POTASSIUM PHENETHICILLIN
Common Name English
PHENETHICILLIN K SALT
Common Name English
PHENETHICILLIN POTASSIUM [JAN]
Common Name English
PHENETHICILLIN POTASSIUM [HSDB]
Common Name English
PHENETICILLIN POTASSIUM [MART.]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((1-OXO-2-PHENOXYPROPYL)AMINO)-, 92S-(2.ALPHA.,5.ALPHA.,6.BETA.))-, MONOPOTASSIUM SALT
Common Name English
MAXIPEN
Brand Name English
ORALOPEN
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
Code System Code Type Description
FDA UNII
70978WUK7C
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
PUBCHEM
23675317
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
CHEBI
31987
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
EVMPD
SUB03742MIG
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID5045546
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
RXCUI
132907
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C84048
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
MERCK INDEX
m8607
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
205-084-4
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
CAS
132-93-4
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
SMS_ID
100000087415
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
HSDB
3167
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
MESH
C100209
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
ChEMBL
CHEMBL1614637
Created by admin on Fri Dec 15 15:19:16 GMT 2023 , Edited by admin on Fri Dec 15 15:19:16 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY